Related Experiment Video

Updated: May 26, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing

Mitchell S Stark1, Susan L Woods, Michael G Gartside

  • 1Queensland Institute of Medical Research, Brisbane, Queensland, Australia.

Nature Genetics
|December 27, 2011
PubMed

Insights

Mutations in MAP3K5 and MAP3K9 genes were identified in melanoma, potentially impacting kinase activity. These genetic alterations may contribute to chemoresistance, offering new therapeutic targets for metastatic melanoma.

Area of Science:

  • Genomics
  • Oncology
  • Molecular Biology

Background:

  • Metastatic melanoma is an aggressive cancer with limited treatment options.
  • Identifying novel somatic mutations is crucial for understanding melanoma pathogenesis and developing targeted therapies.

Purpose of the Study:

  • To identify new somatic mutations in metastatic melanoma, focusing on the mitogen-activated protein (MAP) kinase kinase kinase (MAP3K) family.
  • To investigate the functional impact of identified mutations in MAP3K5 and MAP3K9 on kinase activity and downstream signaling.
  • To explore the role of MAP3K pathway alterations in melanoma chemoresistance.

Main Methods:

  • Whole-exome sequencing of eight melanoma samples.
  • Bioinformatic analysis to identify somatic mutations in MAP3K family genes.
  • Structural modeling to predict the effect of mutations on protein structure and function.
  • In vitro kinase assays to assess the activity of mutated kinases.
  • siRNA-mediated knockdown to attenuate MAP3K9 function in melanoma cells.

Main Results:

  • Somatic mutations in MAP3K5 or MAP3K9 were found in 24% of melanoma cell lines.
  • Mutations were predicted to be inactivating based on position and loss of heterozygosity data.
  • MAP3K5 I780F and MAP3K9 W333* variants exhibited reduced kinase activity in vitro.
  • Downstream MAP kinase phosphorylation was decreased upon overexpression of mutant MAP3K5 or MAP3K9.
  • Attenuation of MAP3K9 function increased melanoma cell viability after temozolomide treatment.

Conclusions:

  • Mutations in MAP3K5 and MAP3K9 are recurrent in melanoma and likely lead to reduced kinase activity.
  • Decreased MAP3K pathway activity may contribute to chemoresistance in melanoma.
  • Targeting the MAP3K pathway could represent a novel therapeutic strategy for melanoma treatment.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...